Wordt geladen...
FGFR inhibitors in cholangiocarcinoma: what’s now and what’s next?
Patients with intrahepatic cholangiocarcinoma (iCCA) face a highly dismal prognosis, due to late stage diagnosis, the relative chemoresistance of the disease, and an overall limited portfolio of established therapeutic concepts. In recent years, a number of next generation sequencing studies have pr...
Bewaard in:
| Gepubliceerd in: | Ther Adv Med Oncol |
|---|---|
| Hoofdauteurs: | , , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
SAGE Publications
2020
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7498964/ https://ncbi.nlm.nih.gov/pubmed/32983265 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1758835920953293 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|